Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses

References

• Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov. 2004;3(3):215-25. doi:10.1038/nrd1331. PMID:15031735
   PubMed Web of Science ®Google Scholar
• Makinson A, Reynes J. The fusion inhibitor enfuvirtide in recent antiretroviral strategies. Curr Opin HIV AIDS. 2009;4(2):150-8. doi:10.1097/COH.0b013e32832498d8. PMID:19339955
   PubMed Web of Science ®Google Scholar
• Qiu Z, Chong H, Yao X, Su Y, Cui S, He Y. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target. AIDS. 2015;29(9):1015-24. doi:10.1097/QAD.0000000000000683. PMID:26125136
   PubMed Web of Science ®Google Scholar
• Chang CH, Hinkula J, Loo M, Falkeborn T, Li R, Cardillo TM, Rossi EA, Goldenberg DM, Wahren B. A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro. PLoS One. 2012;7(7):e41235. doi:10.1371/journal.pone.0041235. PMID:22844444
   PubMed Web of Science ®Google Scholar
• Montero M, van Houten NE, Wang X, Scott JK, The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008;72(1):54-84, table of contents. doi:10.1128/MMBR.00020-07. PMID:18322034
   PubMed Web of Science ®Google Scholar
• Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol. 1993;67(11):6642-7; PMID:7692082
   PubMed Web of Science ®Google Scholar
• Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med. 2005;11(6):615-22. doi:10.1038/nm1244. PMID:15880120
   PubMed Web of Science ®Google Scholar
• Walmsley S, Henry K, Katlama C, Nelson M, Castagna A, Reynes J, Clotet B, Hui J, Salgo M, DeMasi R, et al. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis. 2003;188(12):1827-33. doi:10.1086/379810. PMID:14673761
   PubMed Web of Science ®Google Scholar
• Bianchi E, Joyce JG, Miller MD, Finnefrock AC, Liang X, Finotto M, Ingallinella P, McKenna P, Citron M, Ottinger E, et al. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A. 2010;107(23):10655-60. doi:10.1073/pnas.1004261107. PMID:20483992
   PubMed Web of Science ®Google Scholar
• Lai RP, Hock M, Radzimanowski J, Tonks P, Hulsik DL, Effantin G, Seilly DJ, Dreja H, Kliche A, Wagner R, et al. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J Biol Chem. 2014;289(43):29912-26. doi:10.1074/jbc.M114.569566. PMID:25160627
   PubMed Web of Science ®Google Scholar
• Benen TD, Tonks P, Kliche A, Kapzan R, Heeney JL, Wagner R. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein. J Biomed Sci. 2014;21:79. doi:10.1186/s12929-014-0079-x. PMID:25160824
   PubMed Web of Science ®Google Scholar
• Hanson MC, Abraham W, Crespo MP, Chen SH, Liu H, Szeto GL, Kim M, Reinherz EL, Irvine DJ. Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides. Vaccine. 2015;33(7):861-8. doi:10.1016/j.vaccine.2014.12.045. PMID:25559188
   PubMed Web of Science ®Google Scholar
• Vassell R, He Y, Vennakalanti P, Dey AK, Zhuang M, Wang W, Sun Y, Biron-Sorek Z, Srivastava IK, LaBranche CC, et al. Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein. PLoS One. 2015;10(6):e0128562. doi:10.1371/journal.pone.0128562. PMID:26087072
   PubMed Web of Science ®Google Scholar
• Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, Palese P, Katinger H. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol. 1994;68(6):4031-4; PMID:7514684
   PubMed Web of Science ®Google Scholar
• Borrow P, Moody MA. Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. Immunol Rev. 2017;275(1):62-78. doi:10.1111/imr.12504. PMID:28133804
   PubMed Web of Science ®Google Scholar
• Ljungberg K, Rollman E, Eriksson L, Hinkula J, Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology. 2002;302(1):44-57. doi:10.1006/viro.2002.1547. PMID:12429515
   PubMed Web of Science ®Google Scholar
• Nilsson C, Hejdeman B, Godoy-Ramirez K, Tecleab T, Scarlatti G, Bråve A, Earl PL, Stout RR, Robb ML, Shattock RJ, et al. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial. PLoS One. 2015;10(6):e0131748. doi:10.1371/journal.pone.0131748. PMID:26121679
   PubMed Web of Science ®Google Scholar
• Stenler S, Wiklander OP, Badal-Tejedor M, Turunen J, Nordin JZ, Hallengärd D, Wahren B, Andaloussi SE, Rutland MW, Smith CI, et al. Micro-minicircle Gene Therapy: Implications of Size on Fermentation, Complexation, Shearing Resistance, and Expression. Mol Ther Nucleic Acids. 2014;2:e140. doi:10.1038/mtna.2013.67. PMID:24399204
   PubMedGoogle Scholar
• Kay MA, He CY, Chen ZY, A robust system for production of minicircle DNA vectors. Nat Biotechnol. 2010;28(12):1287-9. doi:10.1038/nbt.1708. PMID:21102455
   PubMed Web of Science ®Google Scholar
• Ljungberg K, Whitmore AC, Fluet ME, Moran TP, Shabman RS, Collier ML, Kraus AA, Thompson JM, Montefiori DC, Beard C, et al. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J Virol. 2007;81(24):13412-23. doi:10.1128/JVI.01799-07. PMID:17913817
   PubMed Web of Science ®Google Scholar
• Strauss JH, Strauss EG, The alphaviruses: gene expression, replication, and evolution. Microbiol Rev. 1994;58(3):491-562; PMID:7968923
   PubMedGoogle Scholar
• Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, Bråve A, Wahren B, Pisa P. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One. 2009;4(9):e7226. doi:10.1371/journal.pone.0007226. PMID:19789652
   PubMed Web of Science ®Google Scholar
• Hallengard D, Bråve A, Isaguliants M, Blomberg P, Enger J, Stout R, King A, Wahren B. A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines. Genet Vaccines Ther. 2012;10(1):5. doi:10.1186/1479-0556-10-5. PMID:22873174
   PubMedGoogle Scholar
• Hallengard D, Wahren B, Brave A. A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity. Viral Immunol. 2013;26(2):163-6. doi:10.1089/vim.2012.0083. PMID:23573980
   PubMed Web of Science ®Google Scholar
• Brave A, Boberg A, Gudmundsdotter L, Rollman E, Hallermalm K, Ljungberg K, Blomberg P, Stout R, Paulie S, Sandström E, et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther. 2007;15(9):1724-33. doi:10.1038/sj.mt.6300235. PMID:17579577
   PubMed Web of Science ®Google Scholar
• Brave A, Gudmundsdotter L, Sandström E, Haller BK, Hallengärd D, Maltais AK, King AD, Stout RR, Blomberg P, Höglund U, et al. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine. 2010;28(51):8203-9. doi:10.1016/j.vaccine.2010.08.108. PMID:20951666
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, deCamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E, et al. Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One. 2013;8(1):e53629. doi:10.1371/journal.pone.0053629. PMID:23349725
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-86. doi:10.1056/NEJMoa1113425. PMID:22475592
   PubMed Web of Science ®Google Scholar
• Joachim A, Nilsson C, Aboud S, Bakari M, Lyamuya EF, Robb ML, Marovich MA, Earl P, Moss B, Ochsenbauer C, et al. Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. PLoS One. 2015;10(4):e0118486. doi:10.1371/journal.pone.0118486. PMID:25874723
   PubMed Web of Science ®Google Scholar
• Wise MC, Hutnick NA, Pollara J, Myles DJ, Williams C, Yan J, LaBranche CC, Khan AS, Sardesai NY, Montefiori D, et al. An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates. J Virol. 2015;89(18):9154-66. doi:10.1128/JVI.00652-15. PMID:26085155
   PubMed Web of Science ®Google Scholar
• Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, Donahue DA, Lorin V, Casartelli N, Noël N, et al. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat Commun. 2016;7:10844. doi:10.1038/ncomms10844. PMID:26936020
   PubMed Web of Science ®Google Scholar
• Qiu S, Yi H, Hu J, Cao Z, Wu Y, Li W. The binding mode of fusion inhibitor T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study. Curr HIV Res. 2012;10(2):182-94. doi:10.2174/157016212799937191. PMID:22339124
   PubMed Web of Science ®Google Scholar
• Veiga AS, Pattenden LK, Fletcher JM, Castanho MA, Aguilar MI. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems. Chembiochem. 2009;10(6):1032-44. doi:10.1002/cbic.200800609. PMID:19283693
   PubMed Web of Science ®Google Scholar
• Rollman E, Hinkula J, Arteaga J, Zuber B, Kjerrström A, Liu M, Wahren B, Ljungberg K. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther. 2004;11(14):1146-54. doi:10.1038/sj.gt.3302275. PMID:15103320
   PubMed Web of Science ®Google Scholar
• Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, et al. Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees. AIDS Res Hum Retroviruses. 2014;30(3):299-311. doi:10.1089/aid.2013.0149. PMID:24090081
   PubMed Web of Science ®Google Scholar
• Frey G, Chen J, Rits-Volloch S, Freeman MM, Zolla-Pazner S, Chen B. Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol. 2010;17(12):1486-91. doi:10.1038/nsmb.1950. PMID:21076402
   PubMed Web of Science ®Google Scholar
• Knudsen ML, Ljungberg K, Tatoud R, Weber J, Esteban M, Liljeström P. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen. PLoS One. 2015;10(2):e0117042. doi:10.1371/journal.pone.0117042. PMID:25643354
   PubMed Web of Science ®Google Scholar
• Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther. 1997;4(12):1341-9. doi:10.1038/sj.gt.3300540. PMID:9472558
   PubMed Web of Science ®Google Scholar
• Bigger BW, Tolmachov O, Collombet JM, Fragkos M, Palaszewski I, Coutelle C. An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J Biol Chem. 2001;276(25):23018-27. doi:10.1074/jbc.M010873200. PMID:11304530
   PubMed Web of Science ®Google Scholar
• Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther. 2003;8(3):495-500. doi:10.1016/S1525-0016(03)00168-0. PMID:12946323
   PubMed Web of Science ®Google Scholar
• Riu E, Chen ZY, Xu H, He CY, Kay MA. Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther. 2007;15(7):1348-55. doi:10.1038/sj.mt.6300177. PMID:17457320
   PubMed Web of Science ®Google Scholar
• Dietz WM, Skinner NE, Hamilton SE, Jund MD, Heitfeld SM, Litterman AJ, Hwu P, Chen ZY, Salazar AM, Ohlfest JR, et al. Minicircle DNA is superior to plasmid DNA in eliciting antigen-specific CD8+ T-cell responses. Mol Ther. 2013;21(8):1526-35. doi:10.1038/mt.2013.85. PMID:23689601
   PubMed Web of Science ®Google Scholar
• Schleef M, Schirmbeck R, Reiser M, Michel ML, Schmeer M. Minicircle: Next Generation DNA Vectors for Vaccination. Methods Mol Biol. 2015;1317:327-39; PMID:26072415
   PubMedGoogle Scholar
• Wang Q, Jiang W, Chen Y, Liu P, Sheng C, Chen S, Zhang H, Pan C, Gao S, Huang W. In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses. J Virol. 2014;88(4):1924-34. doi:10.1128/JVI.02757-13. PMID:24284319
   PubMed Web of Science ®Google Scholar
• Thibault T, Degrouard J, Baril P, Pichon C, Midoux P, Malinge JM. Production of DNA minicircles less than 250 base pairs through a novel concentrated DNA circularization assay enabling minicircle design with NF-κB inhibition activity. Nucleic Acids Res 2017;45(5):e26. doi:10.1093/nar/gkw1034
   PubMed Web of Science ®Google Scholar
• Dervillez X, Hüther A, Schuhmacher J, Griesinger C, Cohen JH, von Laer D, Dietrich U. Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. ChemMedChem. 2006;1(3):330-9. doi:10.1002/cmdc.200500062. PMID:16892368
   PubMed Web of Science ®Google Scholar
• Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses. 1994;10(4):359-69. doi:10.1089/aid.1994.10.359. PMID:7520721
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466-70. doi:10.1038/nature10373. PMID:21849977
   PubMed Web of Science ®Google Scholar
• Krebs SJ, McBurney SP, Kovarik DN, Waddell CD, Jaworski JP, Sutton WF, Gomes MM, Trovato M, Waagmeester G, Barnett SJ, et al. Multimeric scaffolds displaying the HIV-1 envelope MPER induce MPER-specific antibodies and cross-neutralizing antibodies when co-immunized with gp160 DNA. PLoS One. 2014;9(12):e113463. doi:10.1371/journal.pone.0113463. PMID:25514675
   PubMed Web of Science ®Google Scholar
• Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308(5730):1906-8. doi:10.1126/science.1111781. PMID:15860590
   PubMed Web of Science ®Google Scholar
• Sok D, Briney B, Jardine JG, Kulp DW, Menis S, Pauthner M, Wood A, Lee EC, Le KM, Jones M, et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science. 2016;353(6307):1557-1560. doi:10.1126/science.aah3945. PMID:27608668
   PubMed Web of Science ®Google Scholar